Peeling Pores and skin Syndrome is a uncommon autosomal illness with no accepted remedy or remedy
Preliminary scientific web site and pediatric affected person recognized in New Zealand
Firm actively evaluating opening further scientific websites in different nations
ASHBURN, Va., Aug. 06, 2024 (GLOBE NEWSWIRE) — Quoin Prescription drugs Ltd. (NASDAQ: QNRX) (the Firm or Quoin) a scientific stage, specialty pharmaceutical firm centered on growing and commercializing novel therapies for uncommon and orphan ailments, at this time introduced the deliberate initiation of an investigator-led scientific research in New Zealand to judge the security and efficacy of QRX003 in a pediatric affected person with Peeling Pores and skin Syndrome (PSS). QRX003 is Quoin’s most superior pipeline product and is at present being evaluated in two late stage scientific trials in america as a possible remedy for Netherton Syndrome (NS). Each research are being performed below an open Investigational New Drug (IND) utility with the Meals and Drug Administration (FDA).
We’re excited to develop QRX003’s growth into this second indication, peeling pores and skin syndrome, the place it’s believed the mechanism of motion of our product might additionally present a profit for this devastating illness. Given the overlapping nature of how PSS presents, sufferers with the illness are recognized to have been beforehand misdiagnosed as having NS. Presently there aren’t any scientific research listed for peeling pores and skin syndrome on clinicaltrials.gov as actively recruiting and dosing topics and there’s no accepted remedy or remedy, presenting an extra alternative for Quoin to attain the primary regulatory approval for one more uncommon genetic illness, acknowledged Michael Myers, CEO, Quoin Prescription drugs. The deliberate initiation of this research represents the execution of a key pillar of Quoin’s technique to develop the scientific testing of QRX003 into different uncommon and orphan illness indications and we’re actively assessing further alternatives past this one.
QRX003 is a singular entire physique, entire life topical lotion that targets the vicious circle of pores and skin irritation and barrier disruption.
Quoin is conducting two ongoing scientific trials evaluating QRX003 for the remedy of Netherton Syndrome. For extra details about the trials, please go to: https://www.nethertonsyndromeclinicaltrials.com/.
About Peeling Pores and skin Syndrome (PSS)
Generalized inflammatory peeling pores and skin syndrome (PSS) is a uncommon autosomal recessive genodermatosis brought on by loss-of-function disease-causing variants of the corneodesmosin gene (CDSN), leading to extreme shedding of the superficial layers of the dermis. Sufferers typically endure from quite a lot of circumstances together with extreme ache and persistent pruritis (itch). There may be at present no accepted remedy for PSS, and sufferers handle signs utilizing over-the-counter emollients.
About QRX003
QRX003 is a topical lotion, formulated with a proprietary supply know-how, and incorporates a broad- spectrum serine protease inhibitor, whose mechanism of motion is meant to carry out the operate of a particular protein, referred to as LEKTI. The absence of LEKTI in Netherton sufferers results in extreme pores and skin shedding leading to a extremely porous and compromised pores and skin barrier. QRX003 is designed to result in a extra normalized pores and skin shedding course of and the formation of a stronger and simpler pores and skin barrier.
About Quoin Prescription drugs Ltd.
Quoin Prescription drugs Ltd. is an rising specialty pharmaceutical firm centered on growing and commercializing therapeutic merchandise that deal with uncommon and orphan ailments. We’re dedicated to addressing unmet medical wants for sufferers, their households, communities and care groups. Quoin’s progressive pipeline includes three merchandise in growth that collectively have the potential to focus on a broad variety of uncommon and orphan indications, together with Netherton Syndrome, Peeling Pores and skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and others. For extra info, go to: www.quoinpharma.com.
Cautionary Word Concerning Ahead Wanting Statements
The Firm cautions that statements on this press launch that aren’t an outline of historic details are forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995. Ahead-looking statements could also be recognized by means of phrases referencing future occasions or circumstances equivalent to anticipate, intend, plan, anticipate, imagine, and can, amongst others. All statements that replicate the Firm’s expectations, assumptions, projections, beliefs, or opinions in regards to the future, apart from statements of historic truth, are forward-looking statements, together with, with out limitation, statements referring to the Firm’s anticipated money runway, the assumption that the info set from each scientific research might probably be sufficiently sturdy and complete to help an NDA submitting, with out the necessity for any further scientific research in Netherton topics, and the assumption that sure protocol modifications has enhanced the potential for a profitable consequence and Quoin’s merchandise in growth collectively have the potential to focus on a broad variety of uncommon and orphan indications, together with Netherton Syndrome, Peeling Pores and skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. As a result of such statements are topic to dangers and uncertainties, precise outcomes could differ materially from these expressed or implied by such forward-looking statements. These forward-looking statements are based mostly upon the Firm’s present expectations and contain assumptions that will by no means materialize or could show to be incorrect. Precise outcomes and the timing of occasions might differ materially from these anticipated in such forward-looking statements on account of numerous dangers and uncertainties together with, however not restricted to, the Firm might have to boost further funds earlier than deliberate, the scientific research could not generate information which is sufficiently sturdy and complete to help an NDA submitting and the Firm’s skill to acquire regulatory approvals. Extra detailed details about the dangers and uncertainties affecting the Firm is summarized within the Firm’s Annual Report on Kind 10-Okay for the yr ended December 31, 2023 and in different filings the Firm has made and will make with the SEC sooner or later. One shouldn’t place undue reliance on these forward-looking statements, which converse solely as of the date on which they have been made. The Firm undertakes no obligation to replace such statements to replicate occasions that happen or circumstances that exist after the date on which they have been made, besides as could also be required by legislation.
For additional info, contact:
Quoin Prescription drugs Ltd.
Michael Myers, Ph.D., CEO
[email protected]
Investor Relations
PCG Advisory
Jeff Ramson
[email protected]
(646) 863-6341
Supply: Quoin Prescription drugs, Inc.